TY - JOUR
T1 - Low sensitivity and frequent cross-reactions in commercially available antibody detection ELISA assays for Taenia solium cysticercosis
AU - Garcia, Hector H.
AU - Castillo, Yesenia
AU - Gonzales, Isidro
AU - Bustos, Javier A.
AU - Saavedra, Herbert
AU - Jacob, Louis
AU - Del Brutto, Oscar H.
AU - Wilkins, Patricia P.
AU - Gonzalez, Armando E.
AU - Gilman, Robert H.
AU - Tsang, Victor C.W.
AU - Rodriguez, Silvia
AU - Martinez, Manuel
AU - Alvarado, Manuel
AU - Porras, Miguel
AU - Vargas, Victor
AU - Ccjuno, Alfredo
AU - Verastegui, Manuela
AU - Zimic, Mirko
AU - Mayta, Holger
AU - Guerra, Cristina
AU - Castro, Yagahira
AU - Lopez, Maria T.
AU - Gavidia, Cesar M.
AU - Gomez, Luis
AU - Moyano, Luz M.
AU - Gamboa, Ricardo
AU - Muro, Claudio
AU - Vilchez, Percy
AU - Nash, Theodore E.
AU - Mahanty, Siddhartha
AU - Noh, John
AU - Handali, Sukwan
AU - Friedland, Jon
PY - 2018/1/1
Y1 - 2018/1/1
N2 - © 2017 John Wiley & Sons Ltd Objective: To evaluate the diagnostic performance of two commercially available ELISA kits, Novalisa® and Ridascreen®, for the detection of antibodies to Taenia solium, compared to serological diagnosis of neurocysticercosis (NCC) by LLGP-EITB (electro-immunotransfer blot assay using lentil-lectin purified glycoprotein antigens). Methods: Archive serum samples from patients with viable NCC (n = 45) or resolved, calcified NCC (n = 45), as well as sera from patients with other cestode parasites (hymenolepiasis, n = 45 and cystic hydatid disease, n = 45), were evaluated for cysticercosis antibody detection using two ELISA kits, Novalisa® and Ridascreen®. All NCC samples had previously tested positive, and all samples from heterologous infections were negative on LLGP-EITB for cysticercosis. Positive rates were calculated by kit and sample group and compared between the two kits. Results: Compared to LLGP-EITB, the sensitivity of both ELISA assays to detect specific antibodies in patients with viable NCC was low (44.4% and 22.2%), and for calcified NCC, it was only 6.7% and 4.5%. Sera from patients with cystic hydatid disease were highly cross-reactive in both ELISA assays (38/45, 84.4%; and 25/45, 55.6%). Sera from patients with hymenolepiasis cross-reacted in five cases in one of the assays (11.1%) and in only one sample with the second assay (2.2%). Conclusions: The performance of Novalisa® and Ridascreen® was poor. Antibody ELISA detection cannot be recommended for the diagnosis of neurocysticercosis.
AB - © 2017 John Wiley & Sons Ltd Objective: To evaluate the diagnostic performance of two commercially available ELISA kits, Novalisa® and Ridascreen®, for the detection of antibodies to Taenia solium, compared to serological diagnosis of neurocysticercosis (NCC) by LLGP-EITB (electro-immunotransfer blot assay using lentil-lectin purified glycoprotein antigens). Methods: Archive serum samples from patients with viable NCC (n = 45) or resolved, calcified NCC (n = 45), as well as sera from patients with other cestode parasites (hymenolepiasis, n = 45 and cystic hydatid disease, n = 45), were evaluated for cysticercosis antibody detection using two ELISA kits, Novalisa® and Ridascreen®. All NCC samples had previously tested positive, and all samples from heterologous infections were negative on LLGP-EITB for cysticercosis. Positive rates were calculated by kit and sample group and compared between the two kits. Results: Compared to LLGP-EITB, the sensitivity of both ELISA assays to detect specific antibodies in patients with viable NCC was low (44.4% and 22.2%), and for calcified NCC, it was only 6.7% and 4.5%. Sera from patients with cystic hydatid disease were highly cross-reactive in both ELISA assays (38/45, 84.4%; and 25/45, 55.6%). Sera from patients with hymenolepiasis cross-reacted in five cases in one of the assays (11.1%) and in only one sample with the second assay (2.2%). Conclusions: The performance of Novalisa® and Ridascreen® was poor. Antibody ELISA detection cannot be recommended for the diagnosis of neurocysticercosis.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85040132698&origin=inward
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85040132698&origin=inward
U2 - 10.1111/tmi.13010
DO - 10.1111/tmi.13010
M3 - Article
SP - 101
EP - 105
JO - Tropical Medicine and International Health
JF - Tropical Medicine and International Health
SN - 1360-2276
ER -